Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2021-04-07

FDA Approved: EXFORGE — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for EXFORGE (amlodipine besylate and valsartan) filed by Novartis, updating the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Exforge (valsartan; amlodipine)

Snippet

SUPPL AP for EXFORGE (AMLODIPINE BESYLATE AND VALSARTAN)